Key Takeaways
- • UK life sciences venture capital funding declined in 2024 relative to global markets—the only tech sector analyzed where Britain failed to improve its VC share over a decade, according to Carmine Circelli, director of life sciences direct and co-investments at British Business Bank.
- • UK life sciences companies raised £3.7 billion in total funding in 2024 (£2.3 billion from venture capital), representing a 106% increase from 2023, yet this growth masks a widening competitive gap against international markets.
- • Negative market perception of life sciences as a high-risk, lower-return sector compared to alternatives is dampening investor appetite; a 2024 British Business Bank survey found 69% of 42 VC fund managers viewed conditions for raising new funds as "poor or very poor."
- • The UK lacks sufficient active fund managers to support life sciences financing demand, and reliance on long-term investment cycles continues to deter venture capital participation in the sector.
- • Government support expansion and dedicated financing programs are viewed as critical interventions by British Business Bank leadership to restore competitiveness in UK life sciences venture capital, as the sector faces substantial structural funding gaps.
Summary
The UK life sciences venture capital sector faces a deepening competitive disadvantage against global markets despite recent funding gains. In 2024, life sciences became the only technology sector analyzed where the UK failed to improve its global share of venture capital funding over the past decade, according to findings presented at the BioTrinity 2025 conference (1–2 April, London) by Carmine Circelli, director of life sciences direct and co-investments at the British Business Bank.
While UK life sciences companies raised £3.7 billion in total funding in 2024—with £2.3 billion sourced from venture capital and representing a 106% increase from 2023—the absolute growth masks a relative market share erosion. Circelli characterized the situation candidly, noting the industry has "lots of ground to make up" and describing a "growing gap between the British healthcare space and other global markets."
Multiple structural factors are constraining UK life sciences VC investment. Investor sentiment has turned decidedly negative, with the sector perceived as carrying elevated risk and delivering returns below alternative investment opportunities. The long-term capital commitment required for life sciences development further discourages venture investors accustomed to shorter exit cycles. Supply-side constraints are equally problematic: the UK does not maintain a sufficient density of active fund managers capable of deploying capital across the life sciences pipeline. A 2024 British Business Bank survey quantified investor reluctance, finding that 69% of 42 VC fund managers rated conditions for raising new funds as "poor or very poor."
Mark Andrews, director of the life sciences fund at the British Business Bank, emphasized that expanded government support is essential to address these structural gaps. The British Business Bank, established as a government entity to support small and medium businesses through financing and advisory services, is positioning itself as a catalyst for sector recovery. Both British Business Bank executives argue that sustained policy intervention and dedicated government-backed financing mechanisms are prerequisite conditions for restoring the UK's competitive position in global life sciences venture capital.
While UK life sciences companies raised £3.7 billion in total funding in 2024—with £2.3 billion sourced from venture capital and representing a 106% increase from 2023—the absolute growth masks a relative market share erosion. Circelli characterized the situation candidly, noting the industry has "lots of ground to make up" and describing a "growing gap between the British healthcare space and other global markets."
Multiple structural factors are constraining UK life sciences VC investment. Investor sentiment has turned decidedly negative, with the sector perceived as carrying elevated risk and delivering returns below alternative investment opportunities. The long-term capital commitment required for life sciences development further discourages venture investors accustomed to shorter exit cycles. Supply-side constraints are equally problematic: the UK does not maintain a sufficient density of active fund managers capable of deploying capital across the life sciences pipeline. A 2024 British Business Bank survey quantified investor reluctance, finding that 69% of 42 VC fund managers rated conditions for raising new funds as "poor or very poor."
Mark Andrews, director of the life sciences fund at the British Business Bank, emphasized that expanded government support is essential to address these structural gaps. The British Business Bank, established as a government entity to support small and medium businesses through financing and advisory services, is positioning itself as a catalyst for sector recovery. Both British Business Bank executives argue that sustained policy intervention and dedicated government-backed financing mechanisms are prerequisite conditions for restoring the UK's competitive position in global life sciences venture capital.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.